Clinical Trials

Accrual Status
Limit to SWOG Trials

1044 Results

View
Closed
Phase
Accrual
98%
SWOG Clinical Trial Number
S1404

A Phase III Randomized Trial of Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High-Risk Resected Melanoma -
Status Notes
Step 2 (randomization) of the above-referenced study will be permanently closed to accrual effective November 2, 2017 at 11:59 p.m. Pacific Time.

Closure to Step 1 (prestudy screening) was effective August 15th.



NOTE: This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
Melanoma
Symptom Management and Survivorship
Activated
10-15-2015
ClinicalTrials.gov Registry Number
NCT02506153
Closed
Phase
Accrual
98%
SWOG Clinical Trial Number
S1505

A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Status Notes
S1505 is now closed to accrual as of 04/20/2018.
Research Committee(s)
Gastrointestinal Cancer
Activated
10-12-2015
ClinicalTrials.gov Registry Number
NCT02562716
Closed
Phase
Accrual
29%
SWOG Clinical Trial Number
S1403

A Randomized Phase II Trial of Afatinib Plus Cetuximab Versus Afatinib Alone In Treatment-Naïve Patients With Advanced, EGFR Mutation Positive Non-Small Lung Cancer (NSCLC)
Status Notes
This study permanently closed to accrual effective April 23, 2018.
Research Committee(s)
Lung Cancer
Activated
03-25-2015
Closed
04-23-2018
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1316

Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction
Status Notes
Re-Activation - Effective 6/1/18
Research Committee(s)
Cancer Survivorship
Gastrointestinal Cancer
Activated
03-09-2015
ClinicalTrials.gov Registry Number
NCT02270450
Closed
Phase
Accrual
98%
SWOG Clinical Trial Number
S1318

A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia Chromosome Negative (Ph-) Acute Lymphocytic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dastainib-Sensitive Mutations or Kinase Fusions (DSMKF)
Research Committee(s)
Leukemia
Activated
01-12-2015
Closed
09-29-2021
ClinicalTrials.gov Registry Number
02143414
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1406

Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
11-13-2014
Closed
04-01-2016
ClinicalTrials.gov Registry Number
NCT02164916
Closed
Phase
Accrual
1%
SWOG Clinical Trial Number
S1300

A Randomized, Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-Squamous NSCLC Patients Who Have Progressed Systemically After Previous Clinical Benefit from Crizotinib Monotherapy
Status Notes
This study will permanently close to accrual on September 1, 2016 at 11:59 p.m. Pacific.
Research Committee(s)
Lung Cancer
Activated
08-01-2014
Closed
09-01-2016
ClinicalTrials.gov Registry Number
NCT #02134912
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1320

A Randomized Phase II Trial of Intermittent Versus Continuous Dosing Of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma
Status Notes
Effective 7/15/2019, Step 2 registration (randomization) is permanently closed to accrual.

<b>Effective 4/19/19, Step 1 (lead‐in continuous dosing) will be permanently closed to accrual effective April 19, 2019 at 11:59 p.m. Pacific Time.

All patients who have consented must be registered to Step 1 (lead‐in continuous dosing) prior to 11:59 p.m. PT on April 19, 2019 in order to be eligible to participate. This closure does not apply to Step 2 randomization</b>
Research Committee(s)
Melanoma
Activated
07-22-2014
Closed
07-15-2019
ClinicalTrials.gov Registry Number
NCT02199730
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1314

A Randomized Phase II Study of CO-eXpression ExtrapolatioN (COXEN)-Directed Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Research Committee(s)
Genitourinary Cancer
Activated
07-09-2014
Closed
12-01-2017
ClinicalTrials.gov Registry Number
NCT02177695
Closed
Phase
SWOG Clinical Trial Number
S1400

A BIOMARKER-DRIVEN MASTER PROTOCOL FOR PREVIOUSLY TREATED SQUAMOUS CELL LUNG CANCER (LUNG-MAP)
Status Notes
The S1400 screening protocol will close to accrual and be replaced by the new Lung-MAP screening protocol, called LUNGMAP, which will open to accrual January 28, 2019, effective 2:00 pm PST.

This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Head and Neck Cancer
Lung Cancer
Activated
06-15-2014
ClinicalTrials.gov Registry Number
NCT02154490
Closed
Phase
Accrual
83%
SWOG Clinical Trial Number
S1400A

A BIOMARKER-DRIVEN MASTER PROTOCOL FOR PREVIOUSLY TREATED SQUAMOUS CELL LUNG CANCER (LUNG-MAP) - A PHASE II STUDY OF MEDI4736 FOR PREVIOUSLY TREATED PATIENTS WITH STAGE IV SQUAMOUS CELL LUNG CANCER AND NO MATCHING BIOMARKERS (LUNG-MAP SUB-STUDY)
Status Notes
This sub-study will be permanently closed to accrual on 12/18/15 at 2:00 p.m. Pacific
Research Committee(s)
Lung Cancer
Activated
06-15-2014
Closed
11-18-2015
Closed
Phase
Accrual
57%
SWOG Clinical Trial Number
S1400B

A BIOMARKER-DRIVEN MASTER PROTOCOL FOR PREVIOUSLY TREATED SQUAMOUS CELL LUNG CANCER - A PHASE II STUDY OF GDC-0032 (TASELISIB) FOR PREVIOUSLY TREATED PI3K POSITIVE PATIENTS WITH STAGE IV SQUAMOUS CELL LUNG CANCER
Status Notes
Effective 11:59 p.m. Pacific Time on December 12, 2016, S1400B will be permanently closed to accrual.
Research Committee(s)
Lung Cancer
Activated
06-15-2014
Closed
12-12-2016
Closed
Phase
Accrual
81%
SWOG Clinical Trial Number
S1400D

A BIOMARKER DRIVEN MASTER PROTOCOL FOR PREVIOUSLY TREATED SQUAMOUS CELL LUNG CANCER - A PHASE II STUDY OF AZD4547 FOR PREVIOUSLY TREATED FGFR-POSITIVE PATIENTS WITH STAGE IV SQUAMOUS CELL LUNG CANCER
Status Notes
Effective 11:59 p.m. Pacific Time on October 31, 2016, the following sub-study will be permanently closed to accrual.
Research Committee(s)
Lung Cancer
Activated
06-15-2014
Closed
10-31-2016
Closed
Phase
Accrual
91%
SWOG Clinical Trial Number
S1400C

A BIOMARKER-DRIVEN MASTER PROTOCOL FOR PREVIOUSLY TREATED SQUAMOUS CELL LUNG CANCER - A PHASE II STUDYOF PALBOCICLIB FOR PREVIOUSLY TREATED CELL CYCLE GENE ALTERATION POSITIVE PATIENTS WITH STAGE IV SQUAMOUS CELL LUNG CANCER
Status Notes
Effective 11:59 p.m. Pacific Time on September 1, 2016, S1400C will be permanently closed to accrual.
Research Committee(s)
Lung Cancer
Activated
06-15-2014
Closed
Phase
Accrual
3%
SWOG Clinical Trial Number
S1400E

Phase II/III Randomized Study of Rilotumumab plus Erlotinib versus Erlotinib as Second Line Therapy For Biomarker Selected Patients With Squamous Cell Lung Cancer
Status Notes
This sub-study will be permanently closed to accrual on 11/24/2014 at 2:00 p.m. Pacific
Research Committee(s)
Lung Cancer
Activated
06-15-2014
Closed
11-25-2014
Closed
Phase
Accrual
4%
SWOG Clinical Trial Number
S1222

Fulvestrant Alone Versus Fulvestrant and Everolimus Versus Fulvestrant, Everolimus and Anastrozole: A Phase III Randomized Placebo-Controlled Trial In Postmenopausal Patients With Hormone-Receptor Positive Stage IV Breast Cancer.
Status Notes
NOTE: This study is permanently closed to accrual effective 10/15/2015.
Research Committee(s)
Breast Cancer
Activated
05-09-2014
Closed
10-15-2015
ClinicalTrials.gov Registry Number
NCT02137837
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1312

A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients with Relapsed/Refractory CD22-Positive Acute Lymphoblastic Leukemia (including B-ALL, Mixed Phenotypic Leukemia and Burkitt's Leukemia)
Status Notes
Expansion cohort activated to accrual (Dose Level 5) effective10/25/17.

NOTE: This study is open to limited institutions only.

NOTE: This study requires slot reservation prior to registration.
Research Committee(s)
Leukemia
Activated
04-01-2014
Closed
08-02-2019
ClinicalTrials.gov Registry Number
NCT01925131
Closed
Phase
Accrual
60%
SWOG Clinical Trial Number
S1310

Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
02-15-2014
Closed
05-15-2015
ClinicalTrials.gov Registry Number
NCT02042443
Closed
Phase
Accrual
73%
SWOG Clinical Trial Number
S1313

A Phase Ib/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) versus Modified FOLFIRINOX Alone in Patients with Good Performance Status Metastatic Pancreatic Adenocarcinoma
Status Notes
This study is permanently closed effective 07/01/2017.
Research Committee(s)
Gastrointestinal Cancer
Activated
01-06-2014
ClinicalTrials.gov Registry Number
NCT01959139
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1304

A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease
Status Notes
Effective 5/15/16, this study was permanently closed to accrual.
Research Committee(s)
Myeloma
Activated
10-18-2013
Closed
05-15-2016
ClinicalTrials.gov Registry Number
NCT01903811